Impact of P-glycoprotein on intracellular drug concentration in peripheral blood mononuclear cells and K562 cells.

[1]  Y. Kanai,et al.  Functional coupling of organic anion transporter OAT10 (SLC22A13) and monocarboxylate transporter MCT1 (SLC16A1) influencing the transport function of OAT10. , 2022, Journal of pharmacological sciences.

[2]  C. Lindskog,et al.  A single–cell type transcriptomics map of human tissues , 2021, Science Advances.

[3]  R. Menon,et al.  Sodium Hydrogen Exchanger Regulatory Factor-1 (NHERF1) Regulates Fetal Membrane Inflammation , 2020, International journal of molecular sciences.

[4]  I. Ellis,et al.  Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer , 2020, International journal of molecular sciences.

[5]  T. Ebner,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib , 2019, Clinical Pharmacokinetics.

[6]  Masaki Matsumoto,et al.  The jPOST environment: an integrated proteomics data repository and database , 2018, Nucleic Acids Res..

[7]  Christopher S. Hughes,et al.  Single-pot, solid-phase-enhanced sample preparation for proteomics experiments , 2018, Nature Protocols.

[8]  C. Caux,et al.  MDR1 in immunity: friend or foe? , 2018, Oncoimmunology.

[9]  Yuichi Sugiyama,et al.  The Phenomenon of Albumin-Mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates: Prediction of the In Vivo Uptake Clearance from the In Vitro Uptake by Isolated Hepatocytes Using a Facilitated-Dissociation Model , 2018, Drug Metabolism and Disposition.

[10]  Stefan Tenzer,et al.  Evaluation of FASP, SP3, and iST Protocols for Proteomic Sample Preparation in the Low Microgram Range. , 2017, Journal of proteome research.

[11]  C. Pirker,et al.  Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer , 2017, Journal of experimental & clinical cancer research : CR.

[12]  P. Sieger,et al.  pH‐dependent solubility and permeability profiles: A useful tool for prediction of oral bioavailability , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  Devin P. Sullivan,et al.  A subcellular map of the human proteome , 2017, Science.

[14]  H. Kusuhara,et al.  Impact of Experimental Conditions on the Evaluation of Interactions between Multidrug and Toxin Extrusion Proteins and Candidate Drugs , 2016, Drug Metabolism and Disposition.

[15]  G. Warhurst,et al.  In Vitro–In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells , 2016, Drug Metabolism and Disposition.

[16]  K. Maeda,et al.  Usefulness of A Model-Based Approach for Estimating In Vitro P-Glycoprotein Inhibition Potency in a Transcellular Transport Assay. , 2016, Journal of pharmaceutical sciences.

[17]  M. Kawami,et al.  Methotrexate influx via folate transporters into alveolar epithelial cell line A549. , 2015, Drug metabolism and pharmacokinetics.

[18]  Holger Fuchs,et al.  Brain Penetration of WEB 2086 (Apafant) and Dantrolene in Mdr1a (P-Glycoprotein) and Bcrp Knockout Rats , 2014, Drug Metabolism and Disposition.

[19]  Thomas Ebner,et al.  In Vitro Predictability of Drug-Drug Interaction Likelihood of P-Glycoprotein-Mediated Efflux of Dabigatran Etexilate Based on [I]2/IC50 Threshold , 2014, Drug Metabolism and Disposition.

[20]  Thomas Ebner,et al.  Evaluation and Prediction of Potential Drug-Drug Interactions of Linagliptin Using In Vitro Cell Culture Methods , 2013, Drug Metabolism and Disposition.

[21]  A. Crowe,et al.  Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. , 2012, Toxicology and applied pharmacology.

[22]  B. Weill,et al.  Lack of P-glycoprotein induction by rifampicin and phenobarbital in human lymphocytes. , 2010, International journal of pharmaceutics.

[23]  Yoshiya Tanaka,et al.  Tacrolimus, a Calcineurin Inhibitor, Overcomes Treatment Unresponsiveness Mediated by P-glycoprotein on Lymphocytes in Refractory Rheumatoid Arthritis , 2010, The Journal of Rheumatology.

[24]  Y. Sugiyama,et al.  Model Analysis of the Concentration-Dependent Permeability of P-gp Substrates , 2010, Pharmaceutical Research.

[25]  F. Hilberg,et al.  Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). , 2009, Journal of medicinal chemistry.

[26]  W. Sommergruber,et al.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.

[27]  S. Yamashita,et al.  Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. , 2008, Journal of pharmaceutical sciences.

[28]  T. Tsuruo,et al.  Altered Expression and Function of P-Glycoprotein (170 Kda), Encoded by the MDR 1 Gene, in T Cell Subsets from Aging Humans , 1997, Journal of Clinical Immunology.

[29]  L. Benet,et al.  A Human Lymphocyte Based Ex Vivo Assay to Study the Effect of Drugs on P-glycoprotein (p-Gp) Function1 , 2004, Pharmaceutical Research.

[30]  I. Williams,et al.  P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. , 2002, The Journal of antimicrobial chemotherapy.

[31]  D. Toppmeyer,et al.  A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies , 2002 .

[32]  K. Yokogawa,et al.  Uptake of imipramine in rat liver lysosomes in vitro and its inhibition by basic drugs. , 2000, The Journal of pharmacology and experimental therapeutics.

[33]  R. Kim,et al.  Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[34]  G R Wilkinson,et al.  Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[35]  O. Garden,et al.  Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. , 2000, Blood.

[36]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[38]  I. Roninson,et al.  Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. , 1992, Blood.

[39]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[40]  T. Tsuruo,et al.  Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. , 1986, Japanese journal of cancer research : Gann.

[41]  T. Tsuruo,et al.  Establishment and properties of vincristine-resistant human myelogenous leukemia K562. , 1983, Gan.

[42]  Peter Ralph,et al.  Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia , 1976, International journal of cancer.